Ongoing Trials

The Noxopharm clinical drug candidate Veyonda® is being investigated for activity against various forms of cancer, via three trials.

These trials aim to prove that adding Veyonda® to standard cancer treatments will enhance the effectiveness of radiotherapy, chemotherapy and immuno-oncology therapy.

External Beam Radiation (DARRT)
Chemotherapy (CEP)
Immuno-oncology Therapy (IONIC)
Veyonda® is currently not approved in Australia or any other country